Literature DB >> 19497072

Mycophenolate mofetil: effects on cellular immune subsets, infectious complications, and antimicrobial activity.

M L Ritter1, L Pirofski.   

Abstract

Mycophenolate mofetil (MMF) is one of the most frequently used immunosuppressive drugs in solid organ transplant recipients. MMF is an inhibitor of inosine-5'-monophosphate, and is able to preferentially inhibit B-cell and T-cell function. The immunosuppressive abilities of MMF have made it one of the most successful anti-rejection drugs in transplant patients, but patients also appear to have increased susceptibility to infections, specifically cytomegalovirus and BK virus. Despite its association with an increased risk of infection, MMF has also exhibited antimicrobial activity against pathogens including hepatitis C, Pneumocystis jirovecii, and human immunodeficiency virus. A thorough understanding of the functions of MMF on the immune system and interaction with infectious pathogens could be helpful in implementing preventative strategies against opportunistic infections in transplant patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19497072      PMCID: PMC2852585          DOI: 10.1111/j.1399-3062.2009.00407.x

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  65 in total

1.  Abacavir in combination with the inosine monophosphate dehydrogenase (IMPDH)-inhibitor mycophenolic acid is active against multidrug-resistant HIV-1.

Authors:  A Heredia; D Margolis; D Oldach; R Hazen; N Le; R Redfield
Journal:  J Acquir Immune Defic Syndr       Date:  1999-12-01       Impact factor: 3.731

2.  Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity.

Authors:  D Margolis; A Heredia; J Gaywee; D Oldach; G Drusano; R Redfield
Journal:  J Acquir Immune Defic Syndr       Date:  1999-08-15       Impact factor: 3.731

3.  Mycophenolic acid increases apoptosis, lysosomes and lipid droplets in human lymphoid and monocytic cell lines.

Authors:  R G Cohn; A Mirkovich; B Dunlap; P Burton; S H Chiu; E Eugui; J P Caulfield
Journal:  Transplantation       Date:  1999-08-15       Impact factor: 4.939

4.  The influence of mycophenolate mofetil on the incidence and severity of primary cytomegalovirus infections and disease after renal transplantation.

Authors:  C G ter Meulen; J F Wetzels; L B Hilbrands
Journal:  Nephrol Dial Transplant       Date:  2000-05       Impact factor: 5.992

5.  Infectious complications in geriatric renal transplant patients: comparison of two immunosuppressive protocols.

Authors:  H U Meier-Kriesche; G Friedman; M Jacobs; S Mulgaonkar; M Vaghela; B Kaplan
Journal:  Transplantation       Date:  1999-11-27       Impact factor: 4.939

6.  Novel anti-Pneumocystis carinii effects of the immunosuppressant mycophenolate mofetil in contrast to provocative effects of tacrolimus, sirolimus, and dexamethasone.

Authors:  H S Oz; W T Hughes
Journal:  J Infect Dis       Date:  1997-04       Impact factor: 5.226

Review 7.  Safety of mycophenolate mofetil versus azathioprine in renal transplantation: a systematic review.

Authors:  K Wang; H Zhang; Y Li; Q Wei; H Li; Y Yang; Y Lu
Journal:  Transplant Proc       Date:  2004-09       Impact factor: 1.066

8.  The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo.

Authors:  J Neyts; G Andrei; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

9.  Use of the yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infections.

Authors:  J Neyts; A Meerbach; P McKenna; E De Clercq
Journal:  Antiviral Res       Date:  1996-05       Impact factor: 5.970

10.  Incidence of leukopenia and cytomegalovirus disease in kidney transplants treated with mycophenolate mofetil combined with low cyclosporine and steroid doses.

Authors:  F Moreso; D Serón; J M Morales; J M Cruzado; S Gil-Vernet; J L Pérez; X Fulladosa; A Andrés; J M Grinyó
Journal:  Clin Transplant       Date:  1998-06       Impact factor: 2.863

View more
  34 in total

1.  Tonic-clonic seizure following combined treatment of mycophenolate mofetil and acyclovir.

Authors:  Kyoung Min Lee; Mee Kum Kim; Won Ryang Wee; Jin-hak Lee
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-09-21       Impact factor: 3.117

2.  Cytomegalovirus disease in patients with glomerular diseases treated by immunosuppressive treatment.

Authors:  Zeynep Kendi Celebi; Reyhan Calayoglu; Aysun Karasu Yalcı; Serkan Akturk; Sule Sengul; Sim Kutlay; Gokhan Nergizoglu; Sehsuvar Erturk; Neval Duman; Kenan Ates; Kenan Keven
Journal:  Int Urol Nephrol       Date:  2014-09-27       Impact factor: 2.370

3.  A distinct plasmablast and naïve B-cell phenotype in primary immune thrombocytopenia.

Authors:  Shaun M Flint; Adele Gibson; Geoff Lucas; Raghava Nandigam; Louise Taylor; Drew Provan; Adrian C Newland; Caroline O Savage; Robert B Henderson
Journal:  Haematologica       Date:  2016-03-11       Impact factor: 9.941

4.  A high risk of life-threatening infectious complications in mycophenolate mofetil treatment for acute or chronic graft-versus-host disease.

Authors:  Chie Onishi; Kazuteru Ohashi; Takeshi Sawada; Mikako Nakano; Takeshi Kobayashi; Takuya Yamashita; Hideki Akiyama; Hisashi Sakamaki
Journal:  Int J Hematol       Date:  2010-03-10       Impact factor: 2.490

5.  Adverse Effects of Immunosuppression: Infections.

Authors:  Guy Handley; Jonathan Hand
Journal:  Handb Exp Pharmacol       Date:  2022

6.  Transplantation-associated long-term immunosuppression promotes oral colonization by potentially opportunistic pathogens without impacting other members of the salivary bacteriome.

Authors:  Patricia I Diaz; Bo-Young Hong; Jorge Frias-Lopez; Amanda K Dupuy; Mark Angeloni; Loreto Abusleme; Evimaria Terzi; Effie Ioannidou; Linda D Strausbaugh; Anna Dongari-Bagtzoglou
Journal:  Clin Vaccine Immunol       Date:  2013-04-24

7.  Effects of immunosuppression on circulating adeno-associated virus capsid-specific T cells in humans.

Authors:  Elizabeth M Parzych; Hua Li; Xiangfan Yin; Qin Liu; Te-Lang Wu; Gregory M Podsakoff; Katherine A High; Matthew H Levine; Hildegund C J Ertl
Journal:  Hum Gene Ther       Date:  2013-04       Impact factor: 5.695

8.  Pneumocystis jirovecii pneumonitis: cause of acute hypercalcaemia in chronic haemodialysis patient.

Authors:  Florian Garo; Cedric Aglae; Pedram Ahmadpoor; Olivier Moranne
Journal:  BMJ Case Rep       Date:  2020-01-26

9.  Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates.

Authors:  Carmen Unzu; Sandra Hervás-Stubbs; Ana Sampedro; Itsaso Mauleón; Uxua Mancheño; Carlos Alfaro; Rafael Enríquez de Salamanca; Alberto Benito; Stuart G Beattie; Harald Petry; Jesús Prieto; Ignacio Melero; Antonio Fontanellas
Journal:  J Transl Med       Date:  2012-06-15       Impact factor: 5.531

10.  Lung transplant outcomes are influenced by severity of neutropenia and granulocyte colony-stimulating factor treatment.

Authors:  Laneshia Karee Tague; Davide Scozzi; Michael Wallendorf; Brian F Gage; Alexander S Krupnick; Daniel Kreisel; Derek Byers; Ramsey R Hachem; Andrew E Gelman
Journal:  Am J Transplant       Date:  2019-09-26       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.